Status and phase
Conditions
Treatments
About
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
the investigators would like to confirm the real world evidence(RWE) of safety and efficacy after changing to Eybelis ophthalmic solution 0.002%.
Full description
This clinical trial is a single-arm, multicenter, prospective clinical trial, in which participants have consented to participate in the clinical trial are sequentially registered and proceeded.
The participant's participation period is a total of 24 weeks after the 4-week wash-out period, and according to the visit schedule, tests according to medical procedures are conducted at Screening, Baseline, 6, 12, 18, and 24 weeks to collect data on safety and effectiveness.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adults between 19 and 79 years of age.
Normal Tension Glaucoma, Primary open-angle glaucoma, Glaucoma suspect and Ocular hypertension patients.
Patients who have received prostaglandin analogue (PGA) eye drops with preservatives for at least 3 months from the date of consent.
Patients diagnosed with prostaglandin associated peri-orbitopathy due to the use of Prostaglandin analogue (PGA) eye drops with preservatives.
Those who have agreed in writing to participate in this clinical trial.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 1 patient group
Loading...
Central trial contact
UMT aPM; UMT Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal